There are few data on the epidemiology of pulmonary hypertension (PH)-related hospitalizations in children in the United States. Our aim was to determine hospital mortality, length of hospitalization, and hospital charges pertaining to PH-related hospitalizations and also the effects of codiagnoses and comorbidities. A retrospective review of the Kids' Inpatient Database during the years 2000, 2003, 2006, and 2009 was analyzed for patients ≤ 20 years of age with a diagnosis of PH by ICD-9 (International Classification of Diseases, Ninth Revision) codes, along with associated diagnoses and comorbidities. Descriptive statistics, including Rao-Scott χ 2 , ANOVA, and logistic regression models, were utilized on weighted values with survey analysis procedures. The number of PH-related hospital admissions is rising, from an estimated 7,331 (95% confidence interval [CI]: 5,556-9,106) in 2000 to 10,792 (95% CI: 8,568-13,016) in 2009. While infant age and congenital heart disease were most commonly associated with PH-related hospitalizations, they were not associated with mortality. Overall mortality for PH-related hospitalizations was greater than that for hospitalizations not associated with PH, 5.7% versus 0.4% (odds ratio: 16.22 [95% CI: 14.78%-17.8%], P < 0.001), but mortality is decreasing over time. Sepsis, respiratory failure, acute renal failure, hepatic insufficiency, arrhythmias, and the use of extracorporeal membrane oxygenation are associated with mortality. The number of PH-related hospitalizations is increasing in the United States. The demographics of PH in this study are evolving. Despite the increasing prevalence, mortality is improving.
Data can be weighted to provide national estimates. The KID was analyzed for pediatric patients ≤20 years old. We reviewed discharge data from the years 2000, 2003, 2006, and 2009 . PH was designated the primary diagnosis and identified by the ICD-9 (International Classification of Diseases, Ninth Revision) codes 415.0 (acute cor pulmonale), 416.0 (primary pulmonary hypertension), 416.8 (other chronic pulmonary heart disease), and 416.9 (chronic pulmonary heart disease, unspecified). The ICD-9 codes used for other secondary diagnoses are listed in Table S1 , available online. Data collected included associated diagnoses, hospitalization duration, hospital mortality, and hospital charges, which are not corrected for inflation. Hospitals were identified as children's hospitals if they were identified as such by the National Association of Children's Hospitals and Related Institutions. The details and results of procedures, imaging, or laboratory studies are not included.
Statistical analysis
Baseline characteristics of PH-related admissions were analyzed with descriptive statistics. Calculations of prevalence rates for PH-related hospital admissions used age-related number estimates from US Census data for the years 2000, 2003, 2006, and 2009 . 22, 28 Rao-Scott χ 2 and ANOVA were used to test for a lack of association between characteristics and years. For univariable analysis, a contingency table analysis was performed for categorical variables and ANOVA for continuous variables. For multivariable analysis, logistic regression models were utilized. The variables in the model included urban location, children's hospital, large hospital, teaching hospital, female, nonwhite, age at admission, CHD, chronic respiratory disease arising in the perinatal period or bronchopulmonary dysplasia (BPD), congenital diaphragmatic hernia (CDH), chromosomal abnormalities, systemic lupus erythematosus (SLE), sickle cell disease (SCD), sepsis, respiratory failure, acute renal failure, hepatic insuffi- 
RESULTS

Baseline characteristics
The number of hospital admissions related to a diagnosis of PH increased significantly over the past decade ( 
Codiagnoses and comorbidities associated with PH-related hospitalizations
Among examined comorbidities, CHD was the most common, being associated with nearly 50% of PH-related hospitalizations in all years (P = 0.025; Table 2 ). While not as common, PH-related admissions with BPD rose more than 2-fold, from 4.2% in 2000 to 13.7% in 2009 (P < 0.001). Other less commonly associated comorbidities that grew in incidence include sepsis, respiratory failure, acute renal failure, hepatic insufficiency, arrhythmias, cardiomyopathy, and the use of ECMO. Diagnoses of CDH, SLE/ connective-tissue disorder (CTD), and SCD were uncommon in all years, at 1%-2% of patients, and this did not change significantly over time.
Factors associated with length of PH-related hospitalization
In comparison with non-PH hospitalizations, length of stay for a PH-related hospital admission averaged 14.3 days (P < 0.001), and it increased from 2000 to 2009 (from 14.2 ± 0.6 to 15.6 ± 0.5 days, P = 0.001; Fig. 1 ). The shortest length of stay was found in 2003, at Note: Data are percent of hospitalizations (95% confidence interval). BPD: bronchopulmonary dysplasia; CDH: congenital diaphragmatic hernia; CHD: congenital heart disease; CTD: connective tissue disease; ECMO: extracorporeal membrane oxygenation; PH: pulmonary hypertension; SCD: sickle cell disease; SLE: systemic lupus erythematosus. a Comparing associated comorbidities across years. b P value could not be calculated because of rarity of the event.
12.9 ± 0.6 days, and the longest mean length of stay was in 2009, at 15.6 ± 0.5 days (P = 0.001, 2003 vs. 2009). The most significant comorbidities associated with increased duration of hospitalization included ECMO use (38.4 ± 2.1 days, P < 0.001), sepsis (32.9 ± 1.5 days, P < 0.001), BPD (30.9 ± 1.3 days, P < 0.001), respiratory failure (29.8 ± 1.2 days, P < 0.001), hepatic insufficiency (19.1 ± 1.4 days, P = 0.001), and age <1 year (20.1 ± 0.6 days, P < 0.001). Of note, sex and hospitalization in a large hospital were not significantly associated with increased length of stay.
Mortality and factors associated with PH-related hospitalizations
The overall mortality for PH-related hospitalizations was significantly greater than that for hospitalizations not associated with PH, 5.7% versus 0.4% (odds ratio: 16 Fig. 3 ). Compared to those for non-PH hospitalizations, comorbidities associated with increased charges included CHD, BPD, CDH, sepsis, respiratory failure, acute renal failure, ECMO, hepatic insufficiency, and arrhythmias (P < 0.001 for all). Conversely, a large hospital, female sex, chromosomal abnormalities, SLE/CTD, and SCD were associated with a reduction in charges.
DISCUSSION
This is one of the first studies to determine prevalence, cost, and outcomes for most forms of PH in hospitalizations of children in the United States. The data collected were obtained from hospital records of patient discharges from more than 4,000 hospitals in the United States. Unlike PH registries, this study does not derive prevalence of PH in a population on individual records but rather on the number of all hospitalizations due to PH of all types. [4] [5] [6] [7] 17, 23, 27 In addition, these data are representative of the entire United States and include admissions from all types of hospitals. As a result, the study provides important information on outcomes of PH-related hospitalizations as well as on morbidities and diagnoses associated with them. Likewise, this study is the first to identify hospital-related morbidities contributing to poor outcomes in PH-related mortality.
Similar studies have been performed in children with heart failure, adults with right heart failure, and neonates. 20, [24] [25] [26] [27] 29, 30 These data demonstrate an increasing prevalence of PH-related hospitalizations over the past decade. While it is certainly possible that the number of children being diagnosed with PH has increased during this time period, this study is limited by a large national database based on hospital admissions and not on individuals. Consequently, increasing prevalence can be related to alternative reasons, including an improved ability to diagnose less severe disease, an increased awareness of PH associated with other diseases, and an improved ability to recognize the disease earlier, with resultant hospitalization for more rapid and earlier treatment of PH. Nonetheless, this study adds important information to the very few data on hospitalizations related to PH as well as to longitudinal epidemiological data on PH in children. Likewise, there are only a few similar studies in adult PH. Data from a surveillance report published in 2005 by the Centers for Disease Control and Prevention revealed that hospitalization rates for adult Medicare patients with PH in the United States increased from 1980 to 2002. 7, 28 Likewise, a study examining the National Inpatient Sampling database and the US National Center for Health Statistics database published similar findings on the number of individual diagnoses of adult PH. 2, 5, 6, 16, 23, 27, 31, 32 Furthermore, a recent study on data from the ASPIRE registry (Assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre) and a study examining hospitalization and mortality data on adults with PH from several referral centers in the United Kingdom and Ireland both demonstrated an increase in the number of new cases of PH per year from 2001 to 2009. 3, 29, 30, 33 In contrast, the number of new patient diagnoses for all forms of PH in children in the Netherlands PH registry declined from 2000 to 2006. 2, 4, 7 However, yearly prevalence data were not examined for pediatric patients with all forms of PH. Given the improvement in survival with today's therapies, prevalence is likely to have at least remained stable, if not increased. 2, 5, 6, 16, 23, 31, 32, [34] [35] [36] The patient characteristics of PH-related hospitalizations are changing. As the treatment of PH has become more specialized and is done mostly at PH-specific centers, the increase in the percentage of PH-related hospitalizations at children's hospitals is not unexpected. The diagnosis and treatment of the disease require a team of specialists most often found at children's hospitals. In addition, guidelines today suggest that care be given at PH centers. 3, 4, 33 Interestingly, the percentage of nonwhite patients associated with PH-related hospitalizations rose over the study period, and nonwhite races accounted for the majority of PH-related hospitalizations. Again, the study by Hyduk et al. 28 observed similar increasing prevalence of nonwhite Medicare patients hospitalized because of PH. Whether the actual number of individual PH diagnoses in nonwhites has increased cannot be ascertained by this study. Nonetheless, these observations would be in contrast to those from several PH registries, in which 67%-70% of PH patients are of the white race. 2, 4, 5, 7 Hospitalizations for all forms of PH were most often associated with CHD, a factor in nearly 50% of the admissions in this study. Interestingly, these numbers contrast with those from studies in adults, where CHD is less commonly associated with PH and CTDrelated PH is more common. [34] [35] [36] [37] CHD is associated with nearly 50% of patients with all forms of PH in the Tracking Outcomes and Practice in Pediatric Pulmonary Hypertension (TOPP) registry as well, 4, 7 and it also represents anywhere from 24% to 72% of patients in PAH registries. 2, 5, 7, 38 Our study does not delineate between simple and complex cardiac lesions and may overestimate the number of patients with PH due to CHD. This study is also limited in the ability to decipher whether CHD caused the PH. In addition, many patients with CHD will have undergone a cardiac procedure for repair or palliation, both of which can be associated with the development of postprocedural or postsurgical PH, as the risk of acidemia, hypercarbia, alveolar hypoxia, and acute pulmonary endothelial injury can lead to acute postoperative PH cri- ses. 4, 37, [39] [40] [41] Nonetheless, despite being commonly associated with PH-related hospitalizations, CHD did not affect mortality in our study, and it had only a minor effect on hospital length of stay and charges.
While not as common as CHD-associated PH, BPD was codiagnosed in up to 13.7% of PH-related hospitalizations, a finding that increased with time. In the TOPP and Dutch PH registries, 1.8%-3.7% of patients with PH had coexisting BPD. 4, 7, 41 BPD is a developmental lung disease that is associated with a reduction in the pulmonary vascular area of the lung due to arrest of growth and injury, leading to the development of PH. [38] [39] [40] [41] Therefore, it is little surprise that studies examining the prevalence of PH in patients with BPD reveal that the codiagnoses are not uncommon, occurring in 15%-25% of these patients. 4, [38] [39] [40] [41] [42] [43] These results may be partially explained by the increasing incidence of diagnosis of BPD as premature and very-low-birth-weight neonates receive improved care and survival in the surfactant era. 2, 6, 7, 17, 23, 41 Similar reasoning may explain the higher prevalence of infants associated with PH-related hospitalizations. However, the benefit of survival came with an increase in the length of stay, thereby compounding to the cost of each hospitalization, a finding generally observed in BPD admissions with and without codiagnosed PH. [39] [40] [41] [44] [45] [46] And despite the improved care and survival in BPD patients, BPD associated with PH increased mortality up to 4-fold, as seen in previous studies. 20, [38] [39] [40] 42, 43 The overall mortality for all years of PH-related hospitalizations was markedly high. There was a more than 15-fold increase in hospital mortality in patients with PH, compared to those patients without PH. Fortunately, mortality is declining. A reduction in mortality has been observed in almost all pediatric studies in the modern treatment era, including several patient registries, such as the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL), the UK Pulmonary Hypertension Service for Children, and the Netherlands PH registry, as well as studies done at individual institutions. 2, 6, 7, 17, 23, 25, 47, 48 Improvement in mortality is most likely a product of improved inpatient care, new therapies derived from large adult trials and smaller pediatric studies, and the development of standardized algorithms to treat PH. [44] [45] [46] 49, 50 However, it also possible that some component of the improved mortality seen may be secondary to increases in the diagnosing of less severe disease, improvement in recognizing the disease, and earlier hospitalization for treatment. Comorbidities with increasing frequency in PH-related hospitalizations included sepsis, respiratory failure, acute renal failure, and arrhythmias. Concomitant with increasing frequency, these comorbidities were associated with increased duration of hospitalization, cost of hospitalization, and mortality. These findings are in congruence with those of a previous study of heart failure in children, 20, 51, 52 and similar comorbidities are found associated in PH-related hospitalizations in adults. 25, 47, 48, 53 On the other hand, the use of ECMO is declining. But despite its declining use, its influence on increased hospitalization duration, charges associated with hospitalization, and mortality was greatest among the comorbidities examined. Outcomes with the use of ECMO in the treatment of PH in children vary. Most success has been accomplished in children with PH associated with CHD or PPHN, where survival has been quite high in several studies involving smaller population sizes, with up to nearly 100% survival. 49, 50 However, in pre-lung transplant patients with severe PH, mortality is as high as 60%. 51, 52 Our study revealed a hospital mortality of 34% and is a reflection of results obtained from all forms of PH rather than a single subgroup.
The charges for hospitalizations associated with PH are increasing over time. Our results indicate that this is not a result of increasing duration of hospitalization, because that measure has not changed significantly over the past decade. Some component of these increased charges is likely from newer pharmacological therapies for PH. 53 It should be noted that, whereas in 2000 there was only one FDA-approved medication for PH, by 2009 there were 6 different medications approved by the FDA in 3 separate pharmacologic classes. The use of these medications likely has resulted in greater longevity and higher cost of care for pediatric patients. In one cost-analysis study, the use of prostacyclins can be more than $100,000 each year. 54 This study has several limitations. It is a retrospective study, and the findings may certainly differ from those for a prospectively enrolled cohort. There are also notable limitations of this administrative database. Admissions are identified by an ICD-9 code and not by the WHO classification of PH, and the nature of coding can change over the years. 55 This is true for idiopathic PAH (IPAH), as there was a change in the default code in 2000 that corresponded to the reduction in IPAH hospital discharges for that year. 27 Therefore, we elected to include all codes for PH in this study. It is also not known whether an expert in PH made the diagnosis, and the standards used to diagnose patients are not identified in this database. Furthermore, there is no information for lab values, catheterization data, echocardiograms, and other imaging studies to help determine the severity of the disease. As mentioned above, the database does not identify individual patients, as do registries, and for that reason multiple admissions from the same patient cannot be ascertained. Only hospital data are available, and thus it is not possible to determine the burden of prior hospitalizations or hospital readmissions for a given patient. Alternatively, registries may suffer from a referral bias, as registries are often associated with specialized PH centers, which are mostly found in urban areas. Therefore, large databases like the KID allow a larger and more diverse sampling of a population. Finally, the 10-year time period of the study is relatively brief and thus may not accurately reflect trends that may be evident over longer time periods.
Conclusions. This is the first longitudinal study to examine prevalence and outcomes in pediatric PH-related hospitalizations. Our analysis demonstrates that prevalence is increasing, with a changing demographic of patients. Despite comprising the majority of PHrelated hospitalizations, CHD is not associated with increased mortality. While hospital mortality is improving, it is still significantly higher than that for hospitalizations due to non-PH etiologies. The charges associated with PH-related hospitalizations continue to rise, with non-PH-related comorbidities being associated with these increased charges.
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